Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bellerophon Ther Com (BLPH)

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bellerophon to Present at Two September Investor Conferences

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced...

BLPH : 9.45 (+1.39%)
Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Officer

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics: 2Q Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Wednesday reported a loss of $3.8 million in its second quarter.

BLPH : 9.45 (+1.39%)
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics Added to Russell 3000(R) and Microcap(R) Indexes

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company") today announced the closing of its previously announced public offering and concurrent registered direct offering (the "Offerings")...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company") today announced the pricing of offerings for an aggregate of 3,076,923 shares of its common stock at a public offering price...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering....

BLPH : 9.45 (+1.39%)
Company News for May 12, 2020

Companies In The News Are:

BLPH : 9.45 (+1.39%)
MYOK : 130.83 (+0.62%)
APOP : 2.21 (-11.24%)
AMRX : 3.91 (+2.36%)
Bellerophon Therapeutics: 1Q Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Monday reported a loss of $5 million in its first quarter.

BLPH : 9.45 (+1.39%)
Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), ("Bellerophon" or the "Company") a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases,...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse(R) Inhaled Nitric Oxide Therapy to Treat COVID-19

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases,...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse(R) Inhaled Nitric Oxide Therapy for the Treatment of COVID-19

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the submission of an Investigational...

BLPH : 9.45 (+1.39%)
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported...

BLPH : 9.45 (+1.39%)
Companies Seek New Methods to Fight Viral Infections

Infectious diseases such as Ebola, Influenza, Zika, MERS and the recent pandemic that is still spreading, cause enormous loss of life and devastate economies around world. Certain factors influence the...

LITH : 0.1800 (unch)
BSGM : 5.02 (+4.15%)
AYTU : 1.1650 (-2.92%)
BLPH : 9.45 (+1.39%)
NNVC : 3.82 (+0.26%)
Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares...

BLPH : 9.45 (+1.39%)
Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse(R) for the Treatment of COVID-19

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it will host an investor conference...

BLPH : 9.45 (+1.39%)
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it has entered into definitive agreements with several healthcare-focused...

BLPH : 9.45 (+1.39%)
Thinking about buying stock in Alpha Pro Tech, Bellerophon Therapeutics, Cronos Group, Ford, or Snap?

InvestorsObserver issues critical PriceWatch Alerts for APT, BLPH, CRON, F, and SNAP.

APT : 14.27 (+4.62%)
BLPH : 9.45 (+1.39%)
F : 6.51 (-2.25%)
SNAP : 24.43 (+0.45%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar